Apr-19-2006 11:17am From-Pfizer

Customer No. 28880

## RECEIVED CENTRAL FAX CENTER 7346221269

T-176 P.001/003 F-566

APR 1 9 2006

Confirmation No. 6903

Under the Paperwork Reduction Act of 185	5 no person	U.S S 818 recouled to respond to a c	. Patent and	T	PTO/SB/21 (09-04 use through 07/31/2008, OMB 0551-003 fice; U.S. DEPARTMENT OF COMMERC!	
· ·		Application Number	10/717		SALES OF THE COMMUNICATION OF	
TRANSMITTAL		Filing Date	Novem	November 19, 2003		
FORM		First Named Inventor	Jackson	Jackson B. Hester, Jr. et al.		
		Art Unit	1626			
(to be used for all correspondence after initial filing)		Examiner Name	Ebenez	Ebenezer O. Sackey		
Total Number of Pages in This Submission 3		Attorney Docket Number	┥	PC27029A		
ENCLOSURES (Check all that apply)						
Fee Transmittal Form  Fee Attached	Drawlng(s) Licensing-related Papers			A A	ter Allowance Communication to TC  opeal Communication to Board  Appeals and Interferences	
Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application  Reply to Missing Parts  under 37 CFR 1.52 or 1.53	After Final Petition to Provision Power of Change of Cha		Address D und any ad	Aditional fe	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):  all fees as necessary or credit any by given.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name						
Signature	Al					
Printed name Robert N. Young	name Robert N. Young					
Date April 19, 2006	April 19, 2006 Reg. No. 48,412					
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.						
Signature	mi =	1 Kith	_	<u> </u>		
Typed or printed name Diane L. Hetzle	er			Da	Pe April 19, 2006	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual caso. Any commants on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTQ-9199 and select option 2.

USPTO Fax No.

571-273-8300

Apr-19-2006 11:17am From-Pfizer

## RECEIVED CENTRAL FAX CENTER APR 1 9 2006

7346221269

T-176 P.002/003 F-566

USSN: 10/717,237

Ref. No. 27029 (prev. 00587.US1)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

10/717,237

Confirmation No.

6903

Applicant:

Jackson B. Hester, Jr., et al.

Filing Date:

November 19, 2003

Art Unit:

1626

Examiner:

Ebenezer O. Sackey

Docket No:

027029

Mail Stop Commissioner for Patent P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This communication is responsive to an Office Action dated March 24, 2006, imposing a restriction requirement in the above-referenced application. The shortened one-month statutory period is set to expire on April 24, 2006. Accordingly, applicants believe this communication is timely filed. Applicants believe that no additional fee is required for acceptance of this communication. However, should any fees be required, the Patent Office is hereby authorized to charge such fees to Deposit Account No. 23-0455. Applicants likewise believe that no extension of time is required for acceptance of this communication. However, should a petition for extension of time be required for acceptance of this communication, applicants hereby petition for any extensions of time required for timely acceptance of the papers submitted herewith under 37 C.F.R. §1.136, and authorize payment of such extension fees to Deposit Account No. 23-0455.

In response to the restriction requirement, applicants provisionally elect the claims of Group I, claims 1-35 and 40 drawn to compounds and compositions and elect the compound N-[((5S)-3-{3-Fluoro-4-[4-({4-[(4-methylpiperazin-1-yl)methyl]phenoxy}acetyl)piperazin-1-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide, compound 39 from Example 12, for search purposes.